RxDoctor Payments Data

Alicia le Pard, APRN

Family · Gillette, WYNPI 1346470770

Payments from drug & device makers

$871in general payments, 2019–2025

Across 38 payments — averaging $22.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$210
  • Lilly USA, LLC$166
  • Dexcom, Inc.$141
  • AstraZeneca$123
  • Tandem Diabetes Care, Inc.$121
  • Sanofi-aventis U.S. LLC$51
  • plus $59 from 2 others

What the payments were for

  • Food & beverage$85999%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$871 in reported general payments places this provider in the 75th percentile of 284 family providers in Wyoming.

See all family providers in Wyoming

Medicare billing

Part B allowed, 2024
$34,354
Medicare patients
111
Services billed
402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol55$57,547
MounjaroTirzepatide48$41,295
JardianceEmpagliflozin25$39,171
OzempicSemaglutide14$19,959
Humalog Kwikpen U-200Insulin Lispro12$19,038
Tresiba Flextouch U-200Insulin Degludec21$17,725
JanuviaSitagliptin Phosphate12$11,058
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$3,209
Insulin Degludec Pen (U-200)Insulin Degludec12$2,108
NovologInsulin Aspart11$1,835
Oxybutynin Chloride ErOxybutynin Chloride21$1,201
Omeprazole50$948
Losartan Potassium71$810
Levothyroxine Sodium111$759
Atorvastatin Calcium75$704

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$123$57,54755 claims
Lilly USA, LLCMounjaro$166$41,29548 claims
Novo NordiskOzempic, Novolog$210$21,79425 claims
MerckJanuvia$15$11,05812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 284 family providers in Wyoming.

Other family in Gillette

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →